RACK1 and stratifin target ΔNp63α for a proteasome degradation in head and neck squamous cell carcinoma cells upon DNA damage

Cell Cycle

Volumn 3, Issue 10, 2004, Pages 1285-1295

  Fomenkov, Alexey ^a   Zangen, Rachel ^a   Huang, Yi Ping ^a   Osada, Motonobu ^a   Guo, Zhongmin ^a   Fomenkov, Tanya ^a   Trink, Barry ^a   Sidransky, David ^a   Ratovitski, Edward A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cisplatin; p53; p63; RACK1; Stratifin squamous cell carcinomas

Indexed keywords

CISPLATIN; DELTA NP63ALPHA PROTEIN; P63ALPHA PROTEIN; PROTEASOME; PROTEIN; PROTEIN P53; RACK1 PROTEIN; SMALL INTERFERING RNA; STRATIFIN; TAP63 PROTEIN; TAP73 PROTEIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; C TERMINAL DOMAIN; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; DNA DAMAGE; DOWN REGULATION; GENOTOXICITY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; SQUAMOUS CELL CARCINOMA; TRANSACTIVATION; TRANSACTIVATION DOMAIN; WD40 DOMAIN;

EID: 13944255793     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.3.10.1155     Document Type: Article

References (64)

1. Sidransky D, Hollstein M. Clinical implications of the p53 gene. Annu Rev Med 1996; 47:285-301.
2. Soussi T, Beroud C. Assessing TP53 status in human tumors to evaluate clinical outcome. Nature Rev Cancer 2001; 1:233-9.
3. Appella E, Anderson C. Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 2001; 268:2764-72.
4. Kastan M, Onyekwere O, Sidransky D, Vogelstein B, Craig R. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51:6304-11.
5. Giaccia A, Kastan M. The complexity of p53 modulation: Emerging patterns from divergent signals. Genes Dev 1998; 12:2973-83.
6. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan J, Valent A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997; 9:809-19.
7. Trink B, Okami K, Wu L, Sriuranpong V, Jen J, Sidransky D. A new human p53 homologue. Nature Med 1998; 4:747-8.
8. Osada M, Ohba M, Kawahara C, Ishioka C, Kanamaru R, Katoh I, et al. Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nature Med 1998; 4:839-43.
9. Yang A, Kaghad M, Wang Y, Gillett E, Fleming M, Dotsch V, et al. P63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998; 2:305-16.
10. Flores E, Tsai K, Crowley D, Sengupta S, Yang A, McKeon F, et al. P63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 2002; 416:560-4.
11. Hibi K, Trink B, Patturajan M, Westra W, Caballero O, Hill D, et al. AIS is an oncogene amplified in squamous cell carcinoma Proc Natl Acad Sci USA 2000; 97:5462-7.
12. Pozniak C, Barnabe-Heider F, Rymar V, Lee AF, Sadikot A, Miller F. P73 is required for survival and maintenance of CNS neurons. J Neurosci 2002; 22:9800-9.
13. Levrero M, De Laurenzi V, Costanzo A, Gong J, Wang J, Melino G. The p53/p63/p73 family of transcription factors: Overlapping and distinct functions. J Cell Sci 2000; 113:1661-70.
14. Yang A, Kaghad M, Caput D, McKeon F. On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet 2002; 18:90-5.
15. Patturajan M, Nomoto S, Sommer M, Fomenkov A, Hibi K, Zangen R, et al. ΔNp63 induces β-catenin nuclear accumulation and signaling. Cancer Cell 2002; 1:369-79.
16. Koga F, Kawakami S, Kumagai J, Takizawa T, Ando N, Arai G, et al. Impaired ΔNp63 expression associates with reduced β-catenin and aggressive phenotypes of urothelial neoplasms. Br J Cancer 2003; 88:740-7.
17. Wu G, Nomoto S, Hoque M, Dracheva T, Osada M, Lee C, et al. ΔNp63α and TAp63α regulate transcription of genes with distinct biological functions in cancer and development. Cancer Res 2003; 63:2351-7.
18. Parsa R, Yang A, McKeon F, Green H. Association of p63 with proliferative potential in normal and neoplastic human keratinocytes. J Invest Dermatol 1999; 113:1099-105.
19. Ratovitski E, Patturajan M, Hibi K, Trink B, Yamaguchi K, Sidransky D. P53 associates with and targets ΔNp63 into a protein degradation pathway. Proc Natl Acad Sci USA 2001; 98:1817-22.
20. Massion P, Taflan P, Jamshedur Rahman S, Yildiz P, Shyr Y, Edgerton M, et al. Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res 2003; 63:7113-21.
21. Mills A, Zheng B, Wang X, Vogel H, Roop D, Bradley A. P63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999; 398:708-13.
22. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson R, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999; 398:714-8.
23. Hagiwara K, McMenamin M, Miura K, Harris C. Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primers. Cancer Res 1999; 59:4165-9.
24. McGrath J, Duijf P, Doetsch V, Irvine A, de Waal R, Vanmolkot K, et al. Hay-Wells syndrome is caused by heterozygous missense mutations in the SAM domain of p63. Hum Mol Genet 2001; 10:221-9
25. Drut R, Pollono D, Drut R. Bilateral nephroblastoma in familial Hay-Wells syndrome associated with familial reticulate pigmentation of the skin. Am J Med Genet 2002; 110:164-9.
26. Tsutsui K, Asai Y, Fujimoto A, Yamamoto M, Kubo M, Hatta N. A novel p63 sterile α motif (SAM) domain mutation in a Japanese patient with ankyloblepharon, ectodermal defects and cleft lip and palate (AEC) syndrome without ankyloblepharon. Br J Dermatol 2003; 149:395-9.
27. Fomenkov A, Huang Y, Topaloglu O, Brechman A, Osada M, Fomenkov T, et al. p63α mutations lead to aberrant splicing of keratinocyte growth factor receptor in the hay-Wells syndrome. J Biol Chem 2003; 278:23906-14.
28. Pellegrini G, Dellambra E, Golisano O, Martinelli E, Fantozzi I, Bondanza S, et al. p63 identifies keratinocyte stem cells. Proc Natl Acad Sci USA 2001; 98:3156-61.
29. Katoh I, Aisaki K, Kurata S, Ikawa S, Ikawa Y. P51A (TAp63γ), a p53 homolog, accumulates in response to DNA damage for cell regulation. Oncogene 2000; 19:3126-30.
30. Okada Y, Osada M, Kurata S, Sato S, Aisaki K, Kageyama Y, et al. p53 gene family p51 (p63)-encoded, secondary transactivator p51B (TAp63α) occurs without forming an immunoprecipliable complex with MDM2, but responds to genotoxic stress by accumulation. Exp Cell Res 2002; 276:194-200.
31. Liefer K, Koster MI, Wang X, Yang A, McKeon F, Roop D. Down-regulation of p63 is required for epidermal UV-B-induced apoptosis. Cancer Res 2000; 60:4016-20.
32. Boukamp P, Petrussevska R, Breitkreutz D, Hornung J, Markham A, Fusenig N. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 1988; 106:761-71.
33. Elbashir S, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 2001; 15:188-200.
34. Vogelstein B, Kinder K. P53 function and dysfunction. Cell 1992; 70:523-6.
35. Schmitt C, Fridman J, Yang M, Baranov E, Hoffman R, Lowe S. Dissecting p53 tumor suppressor function in vivo. Cancer Cell 2002; 1:289-98.
36. Schwartz D, Rotter V. p53-dependent cell cycle control; response to genotoxic stress. Semin Cancer Biol 1998; 8:325-36.
37. Oren M. Relationship of p53 to the control of apoptotic cell death. Semin Cancer Biol 1994; 5:221-7.
38. Lowe S, Ruley H, Jacks T, Housman D. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 75:957-67.
39. Polyak K, Xia Y, Zweier J, Kinzler K, Vogelstein B. A model for p53-induced apoptosis. Nature 1997; 389:300-5.
40. Johnstone R, Ruefli A, Lowe S. Apoptosis: A link between cancer genetics and chemotherapy. Cell 2002; 108:153-64.
41. Westfall M, Mays D, Sniezek J, Pietenpol J. The ΔNp63α phosphoprotein binds the p21 and 14-3-3 sigma promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutations. Mol Cell Biol 2003; 7:2264-76.
42. Sniezek J, Matheny K, Burkey B, Netterville J, Pietenpol J. Expression of p63 and 14-3-3sigma in normal and hyperdifferentiated mucosa of the upper aerodigestive tract. Otolaryngol Head Neck Surg 2002; 126:598-601.
43. Hermeking H, Lengauer C, Polyak K, He T, Zhang L, Thiagalingam S, et al. 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1997; 1:3-11.
44. Yang H, Wen Y, Chen C, Lozano G, Lee M. 14-3-3 sigma positively regulates p53 and suppresses tumor growth. Mol Cell Biol 2003; 23:7096-107.
45. Tzivion G, Avruch J. 14-3-3 proteins: Active cofactors in cellular regulation by serine/threonine phosphorylation. J Biol Chem 2002; 277:3061-4.
46. Dellambra E, Patrone M, Sparatore B, Negri A, Ceciliani F, Bondanza S, et al. Stratifin, a keratinocyte specific 14-3-3 protein, harbors a pleckstrin homology (PH) domain and enhances protein kinase C activity. J Cell Sci 1995; 108:3569-79.
47. Waterman M, Stavridi E, Waterman J, Halazonetis T. ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nat Genet 1998; 19:175-8.
48. Khanna K, Jackson S. DNA double-strand breaks: Signaling, repair and the cancer connection. Nat Genet 2001; 27:247-54.
49. Ashcroft M, Taya Y, Vousden K. Stress signals utilize multiple pathways to stabilize p53. Mol Cell Biol 2000; 20:3224-33.
50. Levine A. P53, the cellular gatekeeper for growth and division. Cell 1997; 88:323-31.
51. Schechtman D, Mochly-Rosen D. Adaptor proteins in protein kinase C-mediated signal transduction. Oncogene 2001; 20:6339-47.
52. Dohn M, Zhang S, Chen X. P63α and ΔNp63α can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes. Oncogene 2001; 20:3193-205.
53. Ozaki T, Watanabe K, Nakagawa T, Miyazaki K, Takahashi M, Nakagawara A. Function of p73, not of p53, is inhibited by the physical interaction with RACK1 and its inhibitory effect is counteracted by pRB. Oncogene 2003; 21:3231-42.
54. 1/S progression by suppressing src kinase activity. Mol Cell Biol 2004; 24:6788-98.
55. Haupt Y. p53 Regulation: A family affair. Cell Cycle 2004; 3:79-80.
56. Lohrum M, Woods D, Ludwig R, Balint E, Vousden K. C-terminal ubiquitination of p53 contributes to nuclear export. Mol Cell Biol 2001; 21:8521-32.
57. Brooks C, Li M, Gu W. Monoubiquitination: The signal for p53 nuclear export? Cell Cycle 2004; 3:436-8.
58. Dornan D, Wertz I, Shimizu H, Arnott D, Frantz G, Dowd P, et al. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 2004; 429:86-92.
59. Maisse C, Guerrieri P, Melino G. p73 and p63 protein stability: The way to regulate function? Biochem Pharmacol 2003; 66:1555-61.
60. Gu J, Nie L, Kawai H, Yuan Z. Subcellular distribution of p53 and p73 are differentially regulated by MDM2. Cancer Res 2001; 61:6703-7.
61. Michael D, Oren M. The p53 and Mdm2 families in cancer. Curr Opin Genet Dev 2002; 12:53-9.
62. Miyazaki K, Ozaki T, Kato C, Hanamoto T, Fujita T, Irino S, et al. A novel HECT-type E3 ubiquitin ligase, NEDL2, stabilizes p73 and enhances its transcriptional activity. Biochem Biophys Res Commun 2003; 308:106-13.
63. Sidow A, Bulotsky M, Kerrebrock A, Birren B, Altshuler D, Jaenisch R, et al. A novel member of the F-box/WD40 gene family, encoding dactylin, is disrupted in the mouse dactylaplasia mutant. Nat Genet 1999; 23:104-7.
64. Sifakis S, Basel D, Ianakiev P, Kilpatrick M, Tsipouras P. Distal limb malformations: Underlying mechanisms and clinical associations. Clin Genet 2001; 60:165-72.